Series A · Biotech · Valencia, Spain · Founded 2012 · 2–19 employees
Tetraneuron is a clinical-stage biotechnology company developing gene therapies for neurodegenerative diseases, with a primary focus on Alzheimer's disease. Founded in 2012 as a spin-off from Spain's Cajal Institute (CSIC), the company has developed a proprietary platform based on E2F4DN, targeting a master gene regulator of neuronal homeostasis. Their lead candidate TET-101 has demonstrated unique safety and efficacy in preclinical studies, addressing Alzheimer's at its molecular root rather than just symptoms. The company recently secured €4.9 million in funding, led by GIMIC Ventures, to advance towards clinical trials in Europe.
No open roles listed right now.